January 31, 2018
Gemphire Therapeutics seeks evidence for gemcabene as treatment for pediatric nonalcoholic fatty liver disease
Gemphire Therapeutics, a US based clinical-stage biopharmaceutical company focused on therapies for cardiometabolic disorders, including dyslipidemia and Nonalcoholic Steatohepatitis (NASH), has…